Mercy is taking part in a trial that aims to assess the clinical effects of GRAIL’s Galleri® multi-cancer early detection (MCED) test on Medicare recipients.
Up to 50,000 Medicare beneficiaries who have received care in addition to an annual Galleri test will be compared to those who receive care without a Galleri test as part of the three-year REACH trial (NCT05673018). Enrollment aims to identify individuals representative of the Medicare population, especially those historically underrepresented in clinical trials.
“Mercy was the first in our communities to make MCED tests available to our patients and participated in the initial GRAIL clinical study,” stated Dr. Damon Broyles, Mercy’s vice president of clinical innovation, medical director for MCED, and REACH study principal investigator. “We are constantly looking for innovative screening and treatment options, so it was important to us to participate in the REACH study to help expand upon the real-world evidence of the Galleri® test to build upon the evidence base that can help extend access to Medicare beneficiaries.”
Medicare beneficiaries have a severe unmet need for early cancer detection because age is the biggest risk factor for cancer. Ages 65 and older accounted for about 70% of cancer deaths in the United States last year. Medicare seniors who are at the highest risk for cancer because of their age account for more than half of all cancer diagnoses in the United States.
The study is anticipated to be open to patients who are enrolled in Medicare and at least 50 years old.
Disclaimer:
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.
